NWRD09 clinical trials
Also written NWRD09.
How each study uses NWRD09 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the NWRD09 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Newish Biotech (Wuxi) Co., Ltd. (4) · Newish Technology (Beijing) Co., Ltd. (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test NWRD09.
- Dec 2026A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal RegionPhase 1 · Newish Biotech (Wuxi) Co., Ltd.
- Jun 2027Evaluation of NWRD09 for HPV-16 Related Cervical HSILPhase 2 · Newish Biotech (Wuxi) Co., Ltd.
- Sep 2027Evaluation of NWRD09 for Female Participants With Persistent HPV16 InfectionPhase 1/2 · Newish Biotech (Wuxi) Co., Ltd.
Studies
Open first, then newest update. How each study uses NWRD09 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Evaluation of NWRD09 for HPV-16 Related Cervical HSILNot yet recruitingPhase 2Newish Biotech (Wuxi) Co., Ltd.NCT07712692Written as NWRD09 Injection
- A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal RegionRecruitingPhase 1Newish Biotech (Wuxi) Co., Ltd.NCT07710664Written as NWRD09
- Evaluation of NWRD09 for Female Participants With Persistent HPV16 InfectionNot yet recruitingPhase 1/2Newish Biotech (Wuxi) Co., Ltd.NCT07536282Written as NWRD09
- NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical CancerRecruitingNot applicableNewish Technology (Beijing) Co., Ltd.NCT07092007Written as NWRD09 administered by intramuscular injection
- NWRD09 for HPV-16 Related Cervical HSILRecruitingPhase 1Newish Biotech (Wuxi) Co., Ltd.NCT07047989Written as NWRD09 injection
- NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.RecruitingNot applicableNewish Technology (Beijing) Co., Ltd.NCT06741150Written as NWRD09 administered by intramuscular injection